Stay updated on Phase II Pembrolizumab Plus GVD Clinical Trial
Sign up to get notified when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.

Latest updates to the Phase II Pembrolizumab Plus GVD Clinical Trial page
- Check5 days agoChange DetectedThe page’s revision history now includes a new entry for v3.6.5 dated 2026-08-07, along with prior August revisions; this indicates an update to the page’s revision history and timestamps.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, signaling a routine deployment or patch. No study details or user-facing content appears to be altered.SummaryDifference0.0%

- Check27 days agoChange DetectedISRT sections were added (PART 3A/3B) with reference to ISRT guidelines for nodal disease. Eligibility criteria were updated to specify PET-based Lugano measurable disease and autoimmune disease exclusions, and the study endpoints include a 5-year disease-free survival assessment.SummaryDifference1%

- Check41 days agoChange DetectedThe page metadata was updated to reflect a new revision (v3.6.3) and more recent update dates (2026-06-26 and 2026-06-29), indicating an administrative update to the study record.SummaryDifference0.2%

- Check48 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2, indicating a software update to the page. No changes to the displayed study details or layout are evident from this revision.SummaryDifference0.0%

- Check55 days agoChange DetectedNew update dates (2026-06-17, 2026-06-16, 2026-06) were added and older dates (2026-04-16, 2026-04-13, 2026-04) were removed from the update history, signaling recent activity on the study page.SummaryDifference0.2%

Stay in the know with updates to Phase II Pembrolizumab Plus GVD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.